Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.

Thoracic cancer - 1 Dec 2022

Lin Xiaoyi, Lin Xin, Guo Lijuan, Wang Yulei, Zhang Guochun

Abstract excerpt

BACKGROUND: Both TP53 mutation and MYC amplification indicate poor outcomes in breast cancer (BC), but the clinical values of concurrent TP53 and MYC alterations have not been well-characterized. METHODS: A total of 494 BC patients diagnosed at Guangdong Provincial People's Hospital (GDPH) were retrospectively analyzed. Genomic alterations were determined using next-generation sequencing. Survival analysis was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Cancer Treatment Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Genomics

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 36305094
DOI: 10.1111/1759-7714.14703
PMCID: PMC9750818

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.PMID 36305094Read ↗

Characteristics of MYC Amplification and Their Association with Clinicopathological and Molecular Factors in Patients with Breast Cancer.Semantic proximity Read ↗

Molecular alterations and prognosis of breast cancer with cutaneous metastasis.Semantic proximity Read ↗

Molecular alterations and prognosis of breast cancer with cutaneous metastasisSemantic proximity Read ↗

Molecular Landscape of TP53/RB1 Co-Altered Tumors Uncovers Emerging Therapeutic Vulnerabilities.Semantic proximity Read ↗

Real-world Comparison of P53 Immunohistochemistry and TP53 Mutation Analysis Using Next-generation Sequencing.Semantic proximity Read ↗

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigmsSemantic proximity Read ↗

Genetic alterations associated with multiple primary malignancies.Semantic proximity Read ↗

Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.Semantic proximity Read ↗

Genetic interactions reveal distinct biological and therapeutic implications in breast cancer.Semantic proximity Read ↗

P53 immunohistochemistry is an ideal surrogate marker for TP53 mutation and a predictor of early metastasis in breast cancer: Real-world analysisSemantic proximity Read ↗

Significance of Multi-Cancer Genome Profiling Testing for Breast Cancer: A Retrospective Analysis of 3326 Cases from Japan's National Database.Semantic proximity Read ↗

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.